<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982590</url>
  </required_header>
  <id_info>
    <org_study_id>304/PPSP/61313197</org_study_id>
    <nct_id>NCT02982590</nct_id>
  </id_info>
  <brief_title>Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus</brief_title>
  <official_title>Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Sains Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Jantung Negara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiti Sains Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the novel oral anticoagulant apixaban with the&#xD;
      standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus&#xD;
      over 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatment for left ventricular thrombus is anti-coagulant or blood thinning agent&#xD;
      known as warfarin. Recently at least three novel oral anticoagulant agents were used in the&#xD;
      treatment of atrial fibrillation, pulmonary embolism and deep vein thrombosis (DVT).&#xD;
&#xD;
      Novel oral anticoagulant drugs will require no blood taking for INR monitoring, hence less&#xD;
      visit and more convenience to patients. Latest studies also showed lesser rate of bleeding as&#xD;
      compared to warfarin and hence relatively safer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Left Ventricular Thrombus (LVT) Size</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of change in left ventricular thrombus (LVT) size after 12 weeks of Warfarin or Apixaban treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Left Ventricular Thrombosis (LVT) by More Than 50%</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of participants who achieved left ventricular thrombus (LVT) reduction more than 50% in both Warfarin and Apixaban arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Definite Cardiac Embolic Ischemic Stroke</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants who showed evidence of clinically definite cardiac embolic ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Threatening Bleeding</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants who experienced life threatening bleeding attributed to the use of anti-coagulation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Left Ventricular Thrombosis</condition>
  <arm_group>
    <arm_group_label>warfarin sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>warfarin daily, dosage according to INR monitor. Aim INR 2-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 5 MG Oral Tablet [ELIQUIS]</intervention_name>
    <description>Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
    <arm_group_label>apixaban</arm_group_label>
    <other_name>ELIQUIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin Sodium</intervention_name>
    <description>as controlled arm since warfarin is the standard therapy for LV thrombus</description>
    <arm_group_label>warfarin sodium</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - 80 years old&#xD;
&#xD;
          2. Presence of LV thrombus or spontaneous echo contrast (SEC) grade 3 or 4 (Patel VG&#xD;
             1996), with regional wall motion abnormalities&#xD;
&#xD;
          3. HASBLED score less than 3&#xD;
&#xD;
          4. No episodes of major bleeding in the past 6 months a) Major bleeding defined as i.&#xD;
             episodes of bleeding with significant drop in haemoglobin(Hb)level of at least 2gm/dL&#xD;
             - Includes upper and lower gastrointestinal bleed ii. The need for blood transfusion&#xD;
             (pack cell) of at least 2 unit iii. Recent surgery with bleeding complications and&#xD;
             lost of Hb as in (i) or (ii) iv. Any intracranial bleeds with neurological deficits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with unstable arrhythmias and/or recurrent cardiogenic shock&#xD;
&#xD;
          2. Patient with large ischemic stroke on recruitment-defined as involving &gt;1/3 of&#xD;
             cerebral hemisphere or deemed to have high chance of haemorrhagic transformation&#xD;
&#xD;
          3. Patient with permanent pacemaker&#xD;
&#xD;
          4. Patient who is post valve replacement therapy&#xD;
&#xD;
          5. Patient who is pregnant.&#xD;
&#xD;
          6. Patient with advanced kidney disease at stage V and not on dialysis (CrCl &lt;15 mL/min)&#xD;
&#xD;
          7. Patient with advanced liver disease with coagulopathy&#xD;
&#xD;
          8. Patient with organized and old left ventricular thrombus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr W. Yus Haniff W. Isa, M.MED</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Sains Malaysia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universiti Sains Malaysia</name>
      <address>
        <city>Kota Bharu</city>
        <state>Kelanatan</state>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <results_first_submitted>April 27, 2021</results_first_submitted>
  <results_first_submitted_qc>June 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Sains Malaysia</investigator_affiliation>
    <investigator_full_name>Dr W. Yus Haniff W. Isa</investigator_full_name>
    <investigator_title>DR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02982590/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Warfarin Sodium</title>
          <description>warfarin daily, dosage according to INR monitor. Aim INR 2-3&#xD;
Warfarin Sodium: as controlled arm since warfarin is the standard therapy for LV thrombus</description>
        </group>
        <group group_id="P2">
          <title>Apixaban</title>
          <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.&#xD;
Apixaban 5 MG Oral Tablet [ELIQUIS]: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Gender, Age, Co-morbidities, HAS-BLED score</population>
      <group_list>
        <group group_id="B1">
          <title>Warfarin Sodium</title>
          <description>warfarin daily, dosage according to INR monitor. Aim INR 2-3&#xD;
Warfarin Sodium: as controlled arm since warfarin is the standard therapy for LV thrombus</description>
        </group>
        <group group_id="B2">
          <title>Apixaban</title>
          <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.&#xD;
Apixaban 5 MG Oral Tablet [ELIQUIS]: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.00" spread="11.42"/>
                    <measurement group_id="B2" value="55.36" spread="11.04"/>
                    <measurement group_id="B3" value="55.19" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diabetes mellitus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ischemic heart disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial fibrillation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic kidney disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAS-BLED score</title>
          <description>Hypertension, Abnormal renal or liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol (HAS-BLED) score estimates the 1-year risk of major bleeding for patients on anticoagulation to assess risk-benefit in atrial fibrillation care. Minimum score = 0, maximum score = 9.&#xD;
Score of 0 to 1: Low risk for major bleeding. Score of 2: Moderate risk for major bleeding. Score â‰¥ 3: High risk for major bleeding.&#xD;
In our study, we exclude patients with HAS-BLED score &gt; 3. Thus, only patients with HAS-BLED score from 0 to 3 were recruited.</description>
          <units>total score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.46" spread="0.66"/>
                    <measurement group_id="B2" value="1.0" spread="0.68"/>
                    <measurement group_id="B3" value="1.22" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Left Ventricular Thrombus (LVT) Size</title>
        <description>Percentage of change in left ventricular thrombus (LVT) size after 12 weeks of Warfarin or Apixaban treatment</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin Sodium</title>
            <description>Warfarin daily, dosage according to INR monitor. Aim INR 2-3&#xD;
Warfarin Sodium: as controlled arm since warfarin is the standard therapy for LV thrombus</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.&#xD;
Apixaban 5 MG Oral Tablet [ELIQUIS]: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Left Ventricular Thrombus (LVT) Size</title>
          <description>Percentage of change in left ventricular thrombus (LVT) size after 12 weeks of Warfarin or Apixaban treatment</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.45" spread="43.95"/>
                    <measurement group_id="O2" value="-65.08" spread="31.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Left Ventricular Thrombosis (LVT) by More Than 50%</title>
        <description>Percentage of participants who achieved left ventricular thrombus (LVT) reduction more than 50% in both Warfarin and Apixaban arms.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin Sodium</title>
            <description>Warfarin daily, dosage according to INR monitor. Aim INR 2-3&#xD;
Warfarin Sodium: as controlled arm since warfarin is the standard therapy for LV thrombus</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.&#xD;
Apixaban 5 MG Oral Tablet [ELIQUIS]: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Left Ventricular Thrombosis (LVT) by More Than 50%</title>
          <description>Percentage of participants who achieved left ventricular thrombus (LVT) reduction more than 50% in both Warfarin and Apixaban arms.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7"/>
                    <measurement group_id="O2" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Definite Cardiac Embolic Ischemic Stroke</title>
        <description>Number of participants who showed evidence of clinically definite cardiac embolic ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by CT scan</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin Sodium</title>
            <description>Warfarin daily, dosage according to INR monitor. Aim INR 2-3&#xD;
Warfarin Sodium: as controlled arm since warfarin is the standard therapy for LV thrombus</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.&#xD;
Apixaban 5 MG Oral Tablet [ELIQUIS]: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Definite Cardiac Embolic Ischemic Stroke</title>
          <description>Number of participants who showed evidence of clinically definite cardiac embolic ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by CT scan</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Life Threatening Bleeding</title>
        <description>Number of participants who experienced life threatening bleeding attributed to the use of anti-coagulation.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin Sodium</title>
            <description>Warfarin daily, dosage according to INR monitor. Aim INR 2-3&#xD;
Warfarin Sodium: as controlled arm since warfarin is the standard therapy for LV thrombus</description>
          </group>
          <group group_id="O2">
            <title>Apixaban</title>
            <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.&#xD;
Apixaban 5 MG Oral Tablet [ELIQUIS]: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Life Threatening Bleeding</title>
          <description>Number of participants who experienced life threatening bleeding attributed to the use of anti-coagulation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Warfarin Sodium</title>
          <description>Warfarin daily, dosage according to INR monitor. Aim INR 2-3&#xD;
Warfarin Sodium: as controlled arm since warfarin is the standard therapy for LV thrombus</description>
        </group>
        <group group_id="E2">
          <title>Apixaban</title>
          <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.&#xD;
Apixaban 5 MG Oral Tablet [ELIQUIS]: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Worsening heart failure. Died in hospital.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sudden Death at home</sub_title>
                <description>Family informed patient died suddenly at home.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding and Death</sub_title>
                <description>Admitted for upper GI bleeding with coagulopathy. Later develop worsening heart failure and died in hospital.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Stroke with hemorrhagic transformation and death</sub_title>
                <description>Patient develop stroke after off Apixaban 48 hours following end of study. Complicated with hemorrhagic transformation and death.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size of the study was small due to the pilot nature of the study, being a single-center strict study and strict exclusion criteria.&#xD;
High rate of early angioplasty in this center also contributed to the low number of patients with left ventricle thrombus (LVT).&#xD;
Many patients with LVT were excluded because of their ill clinical condition on presentation, deranged renal/liver functions on diagnosis, organized or old LVT and other logistic issues.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>DR W YUS HANIFF W ISA</name_or_title>
      <organization>HOSPITAL UNIVERSITI SAINS MALAYSIA</organization>
      <phone>09-767 3000</phone>
      <email>wyhaniff@usm.my</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

